0 Comments
S-adenosyl-L-methionine (SAMe), cannabidiol (CBD), and kratom in psychiatric disorders: Clinical and mechanistic considerations In Summary Researchers have recently unveiled the benefits and challenges of utilizing cannabidiol (CBD) in the treatment of psychiatric disorders. CBD has been FDA approved for rare epileptic disorders in the United States and has been recognized for its anxiolytic effects. Dosing CBD can be difficult due to various consumption methods, different products offering ratios of CBD: THC (tetrahydrocannabinol) and terpene contents, all of which cause different effects. Along with anxiolytic effects, the anti-inflammatory effects of CBD have also been well documented, acting through various biological mechanisms. Although THC may not be positively recognized for its psychoactive properties, CBD has been documented by major studies to have anxiolytic and antipsychotic effects with added neuroprotective and anticonvulsant effects. The author concludes that due to the minimal side-effects associated with CBD psychiatrists should seriously consider recommending CBD to patients. CBD has fallen into a more of a gray area than THC or cannabis in general as it appears to be widely accepted due to its wide availability yet some overarching associations still think poorly of its use. For example, the National Collegiate Athletic Association (NCAA) explicitly prohibits the use of THC and explains that, while not banned, student-athletes should be hesitant to use CBD products as it increases their risk of testing positive for THC and a healthy athlete should have no reason to utilize CBD anyway. Patients are recommended to seriously discuss their CBD use with a physician and do their research to determine how CBD is received by their places of work or other regulatory bodies they engage in. The study is available for review or download here: View more studies like this in the CED Foundation Archive: http://bit.ly/drcaplan
Parasitic pharmacology- A plausible mechanism of action for cannabidiol In Summary A recent editorial questions the efficacy of utilizing cannabidiol (CBD) as an anti-epileptic and proposes a plausible mechanism of action for previously seen anti-epileptic effects. While discussing the issues within the two randomized-placebo controlled studies published in the New England Journal of Medicine (NEJM) that led to the eventual FDA approval of Edioplex for the treatment of seizures, the author raises concerns about the quality of content published by the NEJM. The author claims that the two studies claiming that CBD was a novel therapy for Dravets Syndrome and Lennox-Gastaut Syndrome did not examine or publish the pharmacokinetic properties of CBD within their study and that all benefits found were actually due to the drug-drug interaction between CBD and clobazam, a known anti-epileptic. As this hypothesis was only examined as a simulation further testing is needed. Cannabinoids, like all drugs, should continue to be questioned and retested for efficiency. Cannabis is not omnipotent and just because it holds promise for a myriad of ailments and disorders does not mean it may be the most efficient or ethical treatment available. Cannabinoids and terpenes deserve to be examined based on their potential as the medical community continues to search for novel cancer treatment, anti-emetics, appetite modulating drugs, and more which can then be fully developed for maximum pharmacological efficiency and compared to the current treatment. It seems irresponsible to not compare or develop cannabis-based medicine considering the promise seen in countless studies. The study is available for review or download here: View more studies like this in the CED Foundation Archive: http://bit.ly/drcaplan
Effects of Cannabidiol on Alcohol-Related Outcomes- A Review of Preclinical and Human Research In Summary A review of preclinical research studies has revealed to possible beneficial effects of cannabidiol on alcohol-related outcomes. It was found that cannabidiol (CBD) is able to lessen alcohol consumption although the mechanism is not well understood. CBD may also protect consumers from the negative effects of alcohol use such as liver and brain damage. It is likely that CBD provides these protective effects through its modulation of inflammatory processes. It is recommended that further research is conducted in order to validate these findings and expand upon the knowledge of how CBD interacts with other common substances. As cannabis-based products become more widely accepted among the medical community and within society it is imperative that the interactions between cannabis and other drugs are known. Those who wish to use cannabis for certain ailments but are already on other medications may consume cannabis and experience negative side-effects due to the interaction of those drugs. Cannabinoids, terpenes, and flavonoids need to be modeled alongside other common medications so that physicians can safely recommend medications and so that pharmacists are able to accurately advise customers when they pick up prescriptions. Research is needed to ensure public safety in this time of evolving medications. The study is available for review or download here: View more studies like this in the CED Foundation Archive: http://bit.ly/drcaplan
|
Archives
April 2021
Categories
All
|